# Program 1 Local Production Readiness Track Phase B-F Bundle

Status: documentation-only governance bundle. Local-only. Synthetic-only unless a later separately authorized track satisfies every applicable gate. Not deployment. Not production use. Not clinical use. Not go-live authorization.

## 1. Purpose and Bundle Boundary

This document defines Program 1 Local Production Readiness Track Phases B through F after completion of Phase A.

The bundle establishes:

- Phase B — Local Machine Security and Access Boundary
- Phase C — Local Execution and No-Network Operating Boundary
- Phase D — Local UI Readiness Gate Without UI Implementation
- Phase E — Real-Data Read-Only Prerequisite Gate
- Phase F — Local Production Readiness Decision Brief and Hold Record

This bundle is documentation-only. It does not implement, configure, deploy, activate, or authorize any runtime capability.

## 2. Explicit Scope

Allowed in this bundle:

- local machine security boundary documentation
- local access and custody requirements
- local execution and no-network operating requirements
- local UI prerequisite criteria without UI implementation
- real-data read-only prerequisite criteria without real-data access
- decision criteria and hold records
- evidence expectations for a future separately authorized review
- continuation of the No-UI Hold
- continuation of the no-real-data and no-go-live boundaries

Prohibited in this bundle:

- Python runtime code
- new CLI commands
- UI, server, API, network, database, or integration implementation
- persistence, export, backup, synchronization, or telemetry implementation
- real-data ingestion, inspection, storage, processing, or transmission
- PHI or PII handling
- clinical workflow behavior
- patient messaging
- appointment mutation
- clinical writeback
- clinical task creation
- autonomous diagnosis, treatment, triage, recommendation, or instruction
- approval, override, clearance, or workflow-enforcement capability
- deployment automation
- production deployment
- go-live authorization

## 3. Phase B — Local Machine Security and Access Boundary

### 3.1 Objective

Define the minimum security and access boundary that would have to exist before the Local Clinician-Facing Synthetic Review Demo could be considered for controlled local evaluation.

Phase B does not configure a machine, create accounts, modify operating-system settings, install security tooling, or approve local use.

### 3.2 Required machine boundary

A future local candidate review must identify one known and accountable machine with:

- a named machine owner or custodian
- a named Program 1 evaluator
- a supported operating system
- current security updates
- full-disk encryption
- authenticated user access
- automatic screen locking
- least-privilege daily operation
- no shared generic account
- no unattended public or patient-accessible placement
- controlled physical access
- documented local path and version identity
- documented removal and decommission procedure

### 3.3 Access boundary

Future access must remain limited to explicitly authorized evaluators. The access model must prohibit:

- anonymous access
- shared credentials
- patient access
- remote public access
- background service exposure
- access through externally reachable ports
- use by personnel outside the approved evaluation purpose
- copying into uncontrolled personal or shared locations

### 3.4 Local custody rules

Before any future candidate execution, a custody record must define:

- who obtained the local copy
- which commit or release candidate is present
- where it is stored
- who may execute it
- when access begins and ends
- how the copy is removed
- how version drift is detected
- how suspected misuse is reported

### 3.5 Security blockers

Phase B remains blocked unless all of the following can be evidenced:

- machine identity
- accountable custodian
- encryption state
- authentication state
- patch state
- least-privilege operating model
- physical access boundary
- copy custody record
- decommission path
- explicit synthetic-only notice

### 3.6 Phase B decision

Documentation complete. Machine security implementation and local evaluation authorization remain outside scope and are not granted.

## 4. Phase C — Local Execution and No-Network Operating Boundary

### 4.1 Objective

Define the operating boundary for a future local synthetic candidate that must not require network connectivity.

Phase C does not alter runtime code, add an offline mode, add network controls, package software, or execute the candidate.

### 4.2 No-network principle

The future candidate must be capable of evaluation without:

- internet access
- local-area-network dependency
- cloud services
- external APIs
- telemetry
- analytics
- update checks
- remote authentication
- remote logging
- database connectivity
- EHR or EMR connectivity
- appointment-system connectivity
- patient-messaging connectivity
- file synchronization

Disconnecting a machine from the network is not, by itself, sufficient evidence of a no-network design. A future review must verify both intended dependencies and observable execution behavior.

### 4.3 Permissible local inputs

Only repository-controlled synthetic scenarios and explicitly approved synthetic evaluation notes may be used.

The future candidate must not accept or invite:

- names
- dates of birth
- contact details
- identifiers
- free-text patient histories
- appointment details
- copied clinical notes
- screenshots of clinical systems
- exported patient records
- any other real-data, PHI, or PII content

### 4.4 Execution constraints

A future local execution plan must define:

- exact approved commit or release candidate
- exact launch path already present in the repository
- expected local files read during execution
- expected local files written during execution, which must remain none unless separately authorized
- expected processes
- expected ports, which must remain none
- expected network calls, which must remain none
- expected termination procedure
- expected cleanup procedure
- expected failure behavior

No new CLI command is authorized by this bundle.

### 4.5 Verification evidence required later

A separately authorized review would require evidence that:

- the candidate starts and operates without connectivity
- no listening server or port is created
- no outbound connection is attempted
- no database is accessed
- no external integration is invoked
- no telemetry is emitted
- no persistence or export is created
- only synthetic content is used
- termination leaves no hidden service running

This document defines evidence expectations only. It does not perform or authorize the verification.

### 4.6 Phase C decision

No-network and local-execution boundaries are defined. Runtime verification, packaging, execution, and deployment remain unstarted and unauthorized.

## 5. Phase D — Local UI Readiness Gate Without UI Implementation

### 5.1 Objective

Define the decision gate that must be passed before any local UI track may be opened.

Phase D does not implement a UI, prototype, browser surface, local web application, server, API, or hosted preview.

No-UI Hold remains active.

### 5.2 Mandatory gate questions

Before a UI track may be considered, reviewers must answer:

1. Why is the existing terminal interface insufficient for the stated synthetic evaluation purpose?
2. What exact user decision would the UI support?
3. Which screens are necessary, and which are explicitly excluded?
4. How will the UI prevent entry of real-data, PHI, or PII?
5. How will it avoid implying clinical approval, completeness, prioritization, or recommendation?
6. How will it remain local-only and non-networked?
7. How will it operate without persistence or export?
8. How will it avoid patient-facing and workflow-control surfaces?
9. Which controls are prohibited?
10. What evidence would justify ending the No-UI Hold?

### 5.3 Required pre-implementation artifacts

A future UI Review Track must produce, before code:

- UI purpose statement
- terminal insufficiency analysis
- user and non-user definition
- screen inventory
- excluded-screen inventory
- data-entry prohibition model
- safety-labeling specification
- navigation model
- state model showing no persistence
- no-network architecture statement
- prohibited control register
- misuse and over-trust analysis
- accessibility review plan
- local execution boundary review
- explicit implementation authorization record

### 5.4 Prohibited UI controls and implications

Any future UI proposal must exclude:

- send
- schedule
- book
- cancel
- approve
- clear
- override
- assign
- escalate
- write back
- create task
- save patient
- export patient
- synchronize
- connect to EHR or EMR
- connect to messaging
- connect to appointment systems

It must also avoid visual treatment that implies:

- diagnosis
- treatment selection
- urgency ranking
- clinical recommendation
- protocol compliance
- completed review
- operational approval
- production readiness

### 5.5 UI gate outcome

The UI gate is not passed by this document. No UI track is opened. No-UI Hold remains active until a separate explicit authorization cites completed prerequisite artifacts.

### 5.6 Phase D decision

Readiness criteria are documented without implementation. UI remains prohibited and unstarted.

## 6. Phase E — Real-Data Read-Only Prerequisite Gate

### 6.1 Objective

Define prerequisites that would have to be satisfied before real-data read-only access could even be considered.

Phase E does not authorize real-data access, PHI or PII handling, patient record viewing, import, query, storage, indexing, transformation, display, logging, or export.

### 6.2 Gate principle

Read-only is not low-risk by default. Viewing real clinical data still creates confidentiality, access, audit, interpretation, retention, incident-response, and accountability obligations.

No real-data track is opened by this bundle.

### 6.3 Mandatory prerequisite domains

A future real-data governance track must complete:

- legal basis and privacy review
- purpose limitation
- data minimization
- PHI and PII classification
- source-system authorization
- identity and access management
- role definition
- least-privilege access
- local storage prohibition or separately governed storage model
- encryption in transit and at rest where applicable
- audit event model
- access logging
- retention and deletion model
- screenshot, clipboard, print, and export policy
- incident-response plan
- breach escalation path
- validation plan
- rollback and access-revocation plan
- clinician accountability model
- training and acceptable-use requirements
- data-processing and vendor review where applicable
- governance approval record

### 6.4 Technical prerequisite questions

Before real-data read-only could be considered, a separate track must establish:

- the exact data source
- the exact fields needed
- why synthetic data is insufficient
- whether identifiers can be removed or minimized
- whether local display requires caching
- whether logs could contain patient information
- whether errors could expose patient information
- how access is authenticated and revoked
- how every access is attributable
- how copied or captured information is controlled
- how version and configuration changes are governed
- how the system fails closed

### 6.5 Clinical and operational exclusions

Even a future read-only authorization would not automatically authorize:

- clinical workflow participation
- recommendations
- triage
- patient messaging
- appointment mutation
- clinical writeback
- task creation
- approval or override
- automated decision-making
- production deployment
- go-live

Each would require a separately named and explicitly authorized track.

### 6.6 Gate outcome

The real-data read-only prerequisite gate is not passed. Required legal, privacy, security, technical, clinical, and operational evidence does not exist within this documentation-only bundle.

### 6.7 Phase E decision

Real-data, PHI, and PII remain prohibited. No real-data track is opened.

## 7. Phase F — Local Production Readiness Decision Brief and Hold Record

### 7.1 Decision summary

Program 1 has completed documentation for Local Production Readiness Track Phases A through F at the boundary-definition level.

The documentation now defines:

- the local-only candidate boundary
- the first permissible synthetic candidate concept
- prohibited local production paths
- local machine security prerequisites
- local access and custody prerequisites
- no-network execution prerequisites
- a UI readiness gate
- a real-data read-only prerequisite gate
- unresolved blockers and hold conditions

### 7.2 What is ready

Ready only as documentation:

- boundary definitions
- prerequisite registers
- prohibited-path registers
- evidence expectations
- decision criteria
- hold records

### 7.3 What is not ready

Not ready and not authorized:

- local deployment
- production use
- UI implementation
- real-data access
- PHI or PII handling
- networked operation
- integrations
- persistence or export
- clinical workflow behavior
- patient communication
- appointment mutation
- clinical writeback
- autonomous clinical behavior
- go-live

### 7.4 Unresolved blockers

The following remain unresolved:

- no approved machine security evidence
- no approved access and custody implementation
- no runtime no-network verification
- no packaging or deployment candidate
- no authorized local execution review
- No-UI Hold remains active
- no UI prerequisite artifacts have been approved
- no legal or privacy approval for real data
- no PHI or PII governance model
- no real-data access control or audit implementation
- no production validation plan
- no operational support model
- no incident-response activation
- no go-live governance record

### 7.5 Hold record

Hold name: Program 1 Local Production Readiness Hold after Phase F.

Hold state:

- documentation-only boundary work complete
- implementation not started
- local deployment not started
- production deployment not started
- UI track not started
- real-data track not started
- clinical workflow track not started
- No-UI Hold active
- synthetic-only boundary active
- no-network expectation active for any future local candidate
- no-persistence and no-export boundary active
- no-go-live state active

### 7.6 Conditions to lift or narrow the hold

The hold may be reconsidered only through a new explicit authorization that:

- names exactly one next track
- states its purpose
- states allowed files and change types
- restates all prohibited capabilities
- identifies required evidence
- defines stopping conditions
- preserves unrelated holds
- does not imply production or clinical approval

Completion of this bundle does not itself satisfy those conditions.

### 7.7 Recommended next decision

`Stop and hold after Local Production Readiness Track Phase F unless one narrowly scoped next track is explicitly authorized.`

No preferred implementation track is implied. The default remains no further change.

## 8. Bundle Closure Confirmations

Confirmed for this Phase B-F bundle:

- documentation-only
- no Python runtime code
- no new CLI command
- no UI implementation
- no server or API
- no network or database capability
- no integration
- no persistence or export
- no real-data, PHI, or PII
- no clinical workflow
- no patient messaging
- no appointment mutation
- no clinical writeback
- no clinical task creation
- no autonomous clinical behavior
- no approval or override capability
- no production deployment
- no go-live authorization
- No-UI Hold remains active
- no UI track was started
- no real-data track was started

## 9. Final Status

Program 1 Local Production Readiness Track Phase B-F Bundle is closed as documentation-only governance work.

The repository remains on hold for implementation, UI, real data, clinical workflow, deployment, production use, and go-live.